COSCIENS Biopharma Inc 6-K, filed Jun 14, 2023
COSCIENS Biopharma Inc. (CSCIF)
About this 6-K
COSCIENS Biopharma Inc filed this 6-K on June 14, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2023
Commission File Number: 001-38064
Aeterna Zentaris Inc.
(Translation of registrant’s name into English)
c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Exhibits 99.1 and 99.2 included with this report on Form 6-K are hereby incorporated by reference into the Registrant’s Registration Statements on Forms S-8 (No. 333-224737, No. 333-210561 and No. 333-200834), Forms F-3 (No. 333-254680) and Forms F-1 (No.333-239264, No. 333-248561 and No. 333-239019) and shall be deemed to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.
DOCUMENTS INDEX
| Exhibit | Description | |
| 99.1 | Report of Voting Results Submitted Pursuant to Section 11.3 of National Instrument 51-102 |
| (2) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AETERNA ZENTARIS INC. | |||
| Date: June 14, 2023 | By: | /s/ Klaus Paulini | |
| Klaus Paulini | |||
| President and Chief Executive Officer | |||
| (3) |
Exhibit 99.1
AETERNA ZENTARIS INC.
Report of Voting Results
Submitted Pursuant to
Section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations
June 14, 2023
In accordance with Section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations, this report describes the matters voted upon and the outcome of the votes at the annual general and special meeting of shareholders of Aeterna Zentaris Inc. (the “Company”) held on June 14, 2023 via live audio webcast. Each of the matters is described in greater detail in the Company’s management information circular dated May 9, 2023 (the “Circular”).
| (a) | The five nominees set forth in the Circular were elected as directors of the Company to hold office until the close of the next annual meeting of the Company’s shareholders or until their successors are duly elected or appointed. The following are the voting results on this matter: |
| FOR | % FOR | AGAINST | % AGAINST | |||||||||||||
| Peter Edwards | 401,912 | 68.94 | % | 181,057 | 31.06 | % | ||||||||||
| Carolyn Egbert | 296,499 | 50.86 | % | 286,470 | 49.14 | % | ||||||||||
| Gilles Gagnon | 402,690 | 69.08 | % | 180,279 | 30.92 | % | ||||||||||
| Dr. Klaus Paulini | 317,211 | 54.41 | % | 265,758 | 45.59 | % | ||||||||||
| Dennis Turpin | 298,514 | 51.21 | % | 284,455 | 48.79 | % | ||||||||||
| (b) | Deloitte LLP was appointed as the Company’s auditors and the directors were authorized to fix the remuneration to be paid to the auditors. The following are the voting results on this matter: |
| FOR | % FOR | WITHHELD | %WITHHELD | |||||||||||||
| Appointment of Auditors | 1,157,809 | 83.18 | % | 234,119 | 16.82 | % | ||||||||||
Dated this 14th day of June, 2023.
|
AETERNA ZENTARIS INC. | ||
| By: | (signed) Giuliano La Fratta | |
| Name: | Giuliano La Fratta | |
| Title: | Chief Financial Officer | |